SNPX Stock Overview
Operates as a clinical-stage biopharmaceutical company. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Synaptogenix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.72 |
| 52 Week High | US$8.78 |
| 52 Week Low | US$2.32 |
| Beta | 1.43 |
| 11 Month Change | -11.75% |
| 3 Month Change | -23.94% |
| 1 Year Change | -56.48% |
| 33 Year Change | -98.83% |
| 5 Year Change | n/a |
| Change since IPO | -96.84% |
Recent News & Updates
Recent updates
We Think Synaptogenix (NASDAQ:SNPX) Can Afford To Drive Business Growth
Sep 20
Companies Like Synaptogenix (NASDAQ:SNPX) Are In A Position To Invest In Growth
May 10Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment
Nov 17Synaptogenix (NASDAQ:SNPX) Is In A Good Position To Deliver On Growth Plans
Oct 05Synaptogenix: The Next Big Thing In Alzheimer's
Jun 16Synaptogenix provides update on phase 2b Alzheimer's disease trial
Jun 09We're Keeping An Eye On Synaptogenix's (NASDAQ:SNPX) Cash Burn Rate
Jun 09Shareholder Returns
| SNPX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 12.8% | 4.0% | 2.0% |
| 1Y | -56.5% | 18.0% | 32.4% |
Return vs Industry: SNPX underperformed the US Biotechs industry which returned 18.3% over the past year.
Return vs Market: SNPX underperformed the US Market which returned 32.6% over the past year.
Price Volatility
| SNPX volatility | |
|---|---|
| SNPX Average Weekly Movement | 11.9% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SNPX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SNPX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 5 | Alan Tuchman | www.synaptogen.com |
Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company. It is conducting clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Its preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders, such as multiple sclerosis, stroke, and traumatic brain injury.
Synaptogenix, Inc. Fundamentals Summary
| SNPX fundamental statistics | |
|---|---|
| Market cap | US$3.67m |
| Earnings (TTM) | -US$9.13m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs SNPX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SNPX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$9.13m |
| Earnings | -US$9.13m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.74 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SNPX perform over the long term?
See historical performance and comparison